Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
5 February 2018 |
Main ID: |
EUCTR2013-000322-66-ES |
Date of registration:
|
08/10/2013 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation
|
Scientific title:
|
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and
safety Outcomes with an eveRolimus-based regiMen (TRANSFORM) - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM) |
Date of first enrolment:
|
21/11/2013 |
Target sample size:
|
2040 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-000322-66 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): yes
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Bulgaria
|
Colombia
|
Croatia
|
Czech Republic
|
Egypt
|
France
|
Germany
|
Greece
|
Guatemala
|
India
|
Indonesia
|
Italy
|
Japan
|
Jordan
|
Korea, Republic of
|
Kuwait
|
Lebanon
|
Malaysia
|
Mexico
|
Netherlands
|
Norway
|
Panama
|
Philippines
|
Poland
|
Portugal
|
Russian Federation
|
Saudi Arabia
|
Singapore
|
Slovakia
|
Slovenia
|
South Africa
|
Spain
|
Sweden
|
Taiwan
|
Thailand
|
Turkey
|
United States
|
Venezuela, Bolivarian Republic of
| | | | | |
Contacts
|
Name:
|
Departamento Médico (ICRO)
|
Address:
|
Gran Via de les Corts catalanes, 764
08013
Barcelona
Spain |
Telephone:
|
+34900353036 |
Email:
|
eecc.novartis@novartis.com |
Affiliation:
|
Novartis Farmacéutica, S.A. |
|
Name:
|
Departamento Médico (ICRO)
|
Address:
|
Gran Via de les Corts catalanes, 764
08013
Barcelona
Spain |
Telephone:
|
+34900353036 |
Email:
|
eecc.novartis@novartis.com |
Affiliation:
|
Novartis Farmacéutica, S.A. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Written informed consent obtained.
2. Male or female subject > and equal 18 years old
3. Subject randomized within 24 hr of completion of transplant surgery.
4. Recipient of a kidney with a cold ischemia time < 30 hours.
5. Recipient of a primary (or secondary, if first graft is not lost due to immunological reasons) renal transplant from a deceased heart beating, living unrelated, living related non-human leukocyte antigen identical or an expanded criteria donor. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 2040 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 200
Exclusion criteria: 1. Subject unable to tolerate oral medication at time of randomization. 2. Use of other investigational drugs at the time of enrollment 3. History of hypersensitivity to any of the study drugs or similar chemical classes. 4. multi-organ transplant recipient 5. Recipient of ABO incompatible allograft or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant 6. high immunological risk by assessment of anti-donor reactivity e.g. high PRA, presence of pre-existing DSA 7. HIV positive 8. HBsAg and/or a HCV positive with evidence of elevated LFTs (ALT/AST levels ? 2.5 times ULN) 9. Recipient of a kidney from a donor who tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) 10. BMI greater than 35 11. severe systemic infections 12. Subject requiring systemic anticoagulation 13. History of malignancy 14. severe restrictive or obstructive pulmonary disorders 15. severe hypercholesterolemia or hypertriglyceridemia 16. white blood cell (WBC) count ? 2,000 /mm3 or with platelet count ? 50,000 /mm3. 17. Pregnant or nursing (lactating) women 18. Women of child-bearing potential
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Body processes [G] - Immune system processes [G12]
|
Adult kidney transplant recipients. MedDRA version: 16.0
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
System Organ Class: 100000004857
|
Intervention(s)
|
Trade Name: Certican 0,25mg Product Name: Certican 0.25mg Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25-
Trade Name: Certican 0,5mg Product Name: Certican 0.5mg Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.50-
Trade Name: Certican 0,75mg Product Name: Certican 0.75mg Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75-
Trade Name: Certican 1mg Product Name: Certican 1.0mg Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.00-
Trade Name: PROGRAF 0,5 mg Product Name: PROGRAF 0,5 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: TACROLIMUS CAS Number: 104987-11-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-
Trade Name: PROGRAF 1MG Product Name: PROGRAF 1 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: TACROLIMUS CAS Number: 104987-11-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-
Trade Name: PROGRAF 5MG Product Name: prograf 5 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: TACROLIMUS CAS Number: 104987-11-3 Other descriptive name: PROGRAF Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5-
Trad
|
Primary Outcome(s)
|
Main Objective: Evaluate the effect of everolimus with reduced exposure CNI versus MPA with standard exposure CNI on the binary composite of treated biopsy-proven acute rejection (tBPAR) or eGFR < 50 mL/min/1.73m2 (estimated glomerular filtration rate by MDRD4 formula) at Month 12 post-transplantation.
|
Secondary Objective: Key secondary objectives:
- To evaluate everolimus with reduced exposure CNI compared to MPA plus standard exposure CNI at 12 months post-transplantation with respect to the composite efficacy failure rate of (treated biopsy proven acute rejection (tBPAR), graft loss or death). - To evaluate the binary composite endpoint of tBPAR or eGFR < 50 mL/min/1.73m2 (MDRD4) Month 12 among compliant subjects.
See protocol section 2.2 for other secondary objectives.
|
Timepoint(s) of evaluation of this end point: At 12-month after transplantation.
|
Primary end point(s): The primary analysis will be performed on the Full Analysis Set following the intent-to-treat principle. The primary endpoint of tBPAR or eGFR (MDRD4) < 50 mL/min/1.73m2 at Month 12 will be tested at the significance level of 0.05. Event rates will be compared between groups using a 2-stage approach (hierarchical testing strategy). First, noninferiority of EVR plus reduced CNI vs. MPA plus standard CNI will be evaluated using a 10% non-inferiority margin. If this is significant, then superiority will be evaluated. Based on the closed testing principle, no multiplicity adjustment will be made for testing for both non-inferiority and superiority.
|
Secondary Outcome(s)
|
Secondary end point(s): With respect to the key secondary endpoint - composite efficacy failure of tBPAR, graft loss or death at Month 12, non-inferiority of EVR plus reduced CNI vs. MPA plus standard CNI will be evaluated at the significance level of 0.05 using a 10% non-inferiority margin based on the Full Analysis Set. To evaluate the binary composite endpoint of tBPAR or eGFR < 50 mL/min/1.73m2 (MDRD4) Month 12 among compliant subjects.
|
Timepoint(s) of evaluation of this end point: At 12-month after transplantation.
|
Secondary ID(s)
|
CRAD001A2433
|
2013-000322-66-DE
|
Source(s) of Monetary Support
|
Novartis Pharma Services AG
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|